Pain Management

Pharmacists in all health care settings commonly see what seems like lifelong refills for cyclobenzaprine for musculoskeletal conditions.

The FDA has rejected KemPharm Inc's benzhydrocodone and acetaminophen (Adapaz), a potential abuse-deterrent treatment for acute pain.

Top news of the day from across the healthcare landscape.

The FDA has approved Espero Pharmaceuticals Inc's nitroglycerin sublingual powder (GoNitro) for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.

A recent experience made me realize that pain management is changing.

Research finds patients are fearful of decreasing or stopping medications.

It may have a funny name, but dormant butt syndrome causes some patients to experience knee, back, or hip pain.

The drug 16-8 was able to stop abdominal pain from pancreas inflammation in mice.

How long an individual can endure pain may provide a clue into the size of his or her social contacts.

Research may lead to new therapeutic strategies for treating allodynia.

Chronic pain and hormone replacement among the most frequently used compounded medications.

Opioid abuse has been garnering more attention as the public and private sectors take steps to address the increasing number of opioid-related overdose deaths.

Failing to properly dispose of unfinished medications can have dire consequences.

Discovery may lead to pharmaceutical compounds that target protein structure.

After total knee replacement surgery, patients younger than 45 years and those aged 75 years or older seem to report more pain and less activity than their peers.

Patients with chronic obstructive pulmonary disease have reductions in their brains' gray matter related to the processing of dyspnea, fear, and sensitivity to painful stimuli.

Neuropathic pain is a chronic nerve pain that can significantly impair a patient's functioning and quality of life.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses the role pharmacists can play in helping physicians interpret urine screens.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses the problems related to inappropriate equianalgesic conversions when performing opioid rotations.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses and debunks the myths and hysteria surrounding the use of opioid therapy in treating non-cancer pain.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses strategies pharmacists can employ to enhance the safe use of chronic opioid therapy.

Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses whether or not allowing pharmacists to dispense naloxone without a prescription can help reduce fatal outcomes.

The FDA has approved Belbuca buccal film for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

The Centers for Disease Control and Prevention released final guidelines today that provide recommendations for prescribers with a goal of improved care and safety of patients being treated for chronic pain.

The risks of undertreating pain in the pediatric population are significant.